UN Migration Agency Selects Kony to Accelerate Digital Strategy to Reach More Migrants
26.7.2017 15:30 | Business Wire
Kony, Inc., a leading enterprise mobility and digital applications company, announced that it has been selected by IOM, the UN Migration Agency, to accelerate its digital strategy and support its vision to provide information and humanitarian services to more migrants and government agencies.
As the world’s leading intergovernmental agency dedicated to the wellbeing, safety and engagement of migrants, IOM will use the Kony AppPlatform to deliver mobile apps, including the MigApp, to provide key information and humanitarian services to migrants worldwide.
IOM works closely with governmental, intergovernmental and non-governmental partners. With 166 member states, over 400 field locations and more than 90 per cent of its staff deployed in the field, mobile applications play a critical role in the success of IOM as one of the lead responders to the world’s worst humanitarian emergencies.
IOM is dedicated to enabling humane and orderly migration, promoting international cooperation on migration, assisting in the development of practical solutions for migration issues and providing humanitarian assistance to migrants, including refugees and internally displaced persons.
Many migrants encounter tremendous challenges throughout their journeys and though many migrants, especially those forcibly displaced or migrating irregularly, carry very few personal possessions, most people do carry a smartphone, which can be a gateway to reliable and practical information on migration and humanitarian services.
IOM intends to use the Kony AppPlatform to build multiple apps to support its mission, not only to empower migrants to take charge of their own journey, but also reduce their dependency on unauthorized entities and processes that are not beneficial to the migrants.
“Since our establishment in 1951, IOM upholds the belief that migration builds resilience,” said Bernardo Mariano, IOM’s Director of the Information and Communication Technology Division. “Migrants are agents of change and development. Our ultimate objective is to reduce the human and financial costs of migration through increased engagement with migrants. We look forward to leveraging Kony’s technology, expertise and secure mobile applications to further our commitment to the principle that humane and orderly migration benefits not just migrants but all of society,” he added.
IOM selected the Kony platform to develop and deliver the MigApp, with the goal of reaching 1 billion migrants and achieving 1 million downloads of the app by 2018. The MigApp is a one-stop-shop application that users can download to their mobile phones for free to access information and services relevant to their migration process.
The goal is to help migrants make informed decisions, provide them with access to services related to their migration process, and allow access to IOM programmes. Features planned for the first phase of MigApp include:
- Remittance comparison allowing migrants to find cost-effective ways to send money home;
- Access to up-to-date practical information on IOM programmes and services;
- “I am a Migrant” space where migrants can share their experiences, tell their stories and upload photos to share with other MigApp users;
- Notification services providing alerts on emergencies, health-care information, and other important information related to their location;
- IOM news;
- Online registration enabling IOM to capture data which can be used to analyse migration patterns and trends.
“We are thrilled to partner with all global leaders, and we take special pride in supporting the mission of the UN Migration Agency,” said Thomas E. Hogan, Chairman and Chief Executive Officer, Kony, Inc. “As a global citizen deeply committed to the communities we serve, our contribution to humanitarian services for the world’s migrants is both important and rewarding.”
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25 | Tiedote
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00 | Tiedote
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03 | Tiedote
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00 | Tiedote
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08 | Tiedote
Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven
Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00 | Tiedote
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme